Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HSCEI June 2026 Index Rebalance: Post-Announcement Positioning

HSCEI June 2026 Index Rebalance: Pre-Implementation Update

HSCEI Index Rebalance: Historical Patterns & Mar '25 Event Analysis

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Event-Driven

<ul>
<li>On 5 March 2026, we published a quantitative event study covering 14 completed HSCEI rebalance events (March 2022 to December 2025) ahead of the 9 March implementation.</li>
<li>We are following up now that the March 2026 cycle has moved into WI3. This note reviews the event against the historical framework.</li>
<li>Scorecard: 2/4 clean matches, 2/4 partial. Both ADDs declined in WI0-4. Mengniu's selloff shifted into WAI after a +6.2 ppt drift.</li>
</ul>


On 5 March 2026, we published a quantitative event study covering 14 completed HSCEI rebalance events (March 2022 to December 2025) ahead of the 9 March implementation.
We are following up now that the March 2026 cycle has moved into WI3. This note reviews the event against the historical framework.
Scorecard: 2/4 clean matches, 2/4 partial. Both ADDs declined in WI0-4. Mengniu's selloff shifted into WAI after a +6.2 ppt drift.


HSCEI Index Rebalance: March 2026 Post-Event Review

Horizon Robotics

HSCEI Index Rebalance: March 2026 Post-Event Review